Skip to main content
OpenTrials
Completed

NCT Number: NCT06603090

Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season

This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Behavior COVID-19 Coronaviridae Infections Coronavirus Infections Health Behavior Infections Influenza, Human Lung Diseases Nidovirales Infections Orthomyxoviridae Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Treatment Adherence and Compliance Treatment Refusal Vaccination Hesitancy Vaccination Refusal Virus Diseases

Age range

6 month–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

American Academy of Pediatrics, Itasca, Illinois, United States

Loading trial locations.

About this study

The study is to be conducted over the 1st season (September 2024-April 2025) as an effectiveness trial and the 2nd (September 2025-April 2026) as a replication study. This protocol covers the first season. Parents of eligible children who are 6 month-17 year-old who are due for both a COVID-19 and influenza vaccine will be sent text messages. Within each practice site, parents of eligible children will be randomized to receive either: 1) combined COVID-19 and influenza vaccine text message reminders, 2) COVID-19 reminders alone, 3) influenza reminders alone, or 4) no reminders (usual care).

Randomization is to be stratified by practice site, age group and prior year's COVID-19/influenza vaccine history. Messages will be sent centrally and managed by the research team.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Child that:
  • is 6 months-17 year-old children
  • due for both a COVID-19 and influenza vaccine
  • Receives care at study site
  • Language listed in electronic health record is English or Spanish
  • Has not opted out of text messages from practice

Exclusion criteria

  • Has opted out of text messages from practice
  • Language listed in electronic health record is not English or Spanish

Treatment and study plan

Text message influenza vaccine reminders

Behavioral

Text message influenza vaccine reminders

Text message COVID-19 vaccine reminders

Behavioral

Text message COVID-19 vaccine reminders

Text message influenza and COVID-19 vaccine reminders

Behavioral

Text message influenza and COVID-19 vaccine reminders

Primary outcomes

  1. Timeliness of influenza vaccination

    Time frame: Up to December 31 each year, up to ~90 days

    Days from study start to influenza vaccine up to December 31 each year

  2. Timeliness of COVID-19 vaccination

    Time frame: Up to December 31 each year, up to ~90 days

    Days from study start to COVID-19 vaccine up to December 31 each year

Secondary outcomes

  1. Timeliness of influenza vaccination

    Time frame: Up to April 30 each year, up to ~210 days

    Days from study start to influenza vaccine up to April 30 each year

  2. Timeliness of COVID-19 vaccination

    Time frame: Up to April 30 each year, up to ~210 days

    Days from study start to COVID-19 vaccine up to April 30 each year

  3. Percentage of Participants Who Received Influenza Vaccine by December 31 Each Year

    Time frame: ~3 months

    Receipt of influenza vaccine by December 31 each year

  4. Percentage of Participants Who Received COVID-19 Vaccine by December 31 Each Year

    Time frame: ~3 months

    Receipt of COVID-19 vaccine by December 31 each year

  5. Percentage of Participants Who Received Influenza Vaccine by April 30 Each Year

    Time frame: ~7 months

    Receipt of influenza vaccine by April 30 each year

  6. Percentage of Participants Who Received COVID-19 Vaccine by April 30 Each Year

    Time frame: ~7 months

    Receipt of COVID-19 vaccine by April 30 each year

Sponsors and collaborators

Lead sponsor

Columbia University

Other

Collaborators

  • American Academy of Pediatrics
  • Children's Hospital of Philadelphia
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of Pennsylvania

Registry information

Official study title

Text4Vax: Understanding the Effectiveness and Implementation of Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-2025 Season

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Sep 19, 2024
Registry last updated
Jul 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.